
## Abdel-Moneim M Osman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7979602/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells. BMC Pharmacology & Toxicology, 2021, 22, 8.	1.0	12
2	Astaxanthin Extenuates the Inhibition of Aldehyde Dehydrogenase and Klotho Protein Expression in Cyclophosphamideâ€Induced Acute Cardiomyopathic Rat Model. Clinical and Experimental Pharmacology and Physiology, 2021, , .	0.9	4
3	Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. Journal of Oncology Pharmacy Practice, 2020, 26, 434-444.	0.5	93
4	Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals. Cancer Cell International, 2019, 19, 191.	1.8	21
5	Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells. Breast Cancer Management, 2019, 8, BMT31.	0.2	6
6	Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharmaceutical Journal, 2016, 24, 485-493.	1.2	49
7	Dibutyl phthalate induces oxidative stress and impairs spermatogenesis in adult rats. Toxicology and Industrial Health, 2016, 32, 1467-1477.	0.6	84
8	Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells. Molecular Medicine Reports, 2015, 12, 1368-1374.	1.1	20
9	Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells. Cancer Cell International, 2015, 15, 104.	1.8	13
10	Chemosensitizing and nephroprotective effect of resveratrol in cisplatin –treated animals. Cancer Cell International, 2015, 15, 6.	1.8	36
11	Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection. Saudi Pharmaceutical Journal, 2015, 23, 515-522.	1.2	5
12	Amelioration of doxorubicin-induced cardiotoxicity by resveratrol. Molecular Medicine Reports, 2014, 10, 1455-1460.	1.1	60
13	Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell International, 2013, 13, 52.	1.8	51
14	Acylated pregnane glycosides from Caralluma quadrangula. Phytochemistry, 2013, 88, 54-60.	1.4	29
15	Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell International, 2012, 12, 47.	1.8	59
16	Mechanisms of Cardioprotective Effect of Aged Garlic Extract Against Doxorubicin-Induced Cardiotoxicity. Integrative Cancer Therapies, 2012, 11, 364-370.	0.8	27
17	In vitro cytotoxic screening of selected Saudi medicinal plants. Journal of Natural Medicines, 2012, 66, 406-412.	1.1	67
18	Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food and Chemical Toxicology, 2010, 48, 951-956.	1.8	76

#	Article	IF	CITATIONS
19	Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food and Chemical Toxicology, 2009, 47, 2425-2430.	1.8	25
20	Effect of Protein Depletion on Host and Tumor Response to Paclitaxel in Experimental Animals. International Journal of Pharmacology, 2009, 5, 173-177.	0.1	1
21	Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology, 2006, 222, 103-113.	2.0	17
22	Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines. Biochemical Pharmacology, 2005, 70, 725-732.	2.0	9
23	Progression of Cisplatin-Induced Nephrotoxicity in a Carnitine-Depleted Rat Model. Chemotherapy, 2004, 50, 162-170.	0.8	37
24	Synthesis and biological evaluation of new thiazolopyrimidines. Archives of Pharmacal Research, 2004, 27, 471-477.	2.7	29
25	New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. Cancer Chemotherapy and Pharmacology, 2003, 52, 411-416.	1.1	28
26	Increased Plasma Endothelinâ€1 and Cardiac Nitric Oxide during Doxorubicinâ€Induced Cardiomyopathy. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 140-144.	0.0	9
27	Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 140-144.	0.0	61
28	PREVENTION OF CISPLATIN-INDUCED NEPHROTOXICITY BY METHIMAZOLE. Pharmacological Research, 2000, 41, 113-119.	3.1	24
29	PROPIONYL- ? -CARNITINE AS POTENTIAL PROTECTIVE AGENT AGAINST ADRIAMYCIN-INDUCED IMPAIRMENT OF FATTY ACID BETA-OXIDATION IN ISOLATED HEART MITOCHONDRIA. Pharmacological Research, 2000, 41, 143-150.	3.1	42
30	REVERSAL OF DOXORUBICIN-INDUCED CARDIAC METABOLIC DAMAGE BYL-CARNITINE. Pharmacological Research, 1999, 39, 289-295.	3.1	42
31	Diltiazem Potentiation of Doxorubicin Cytotoxicity and Cellular Uptake in Ehrlich Ascites Carcinoma Cells. Chemotherapy, 1995, 41, 368-377.	0.8	10
32	Effect of Desferrioxamine on Cisplatin-induced Nephrotoxicity in Normal Rats. Chemotherapy, 1995, 41, 448-454.	0.8	29
33	Enhancement of Doxorubicin-Induced Cytotoxicity by Hyperthermia in Ehrlich Ascites Cells. Chemotherapy, 1994, 40, 188-194.	0.8	8
34	Pharmacokinetic Profile of Methotrexate and 5-Fluorouracil in Normal and Bilharzial-infested Mice. Chemotherapy, 1994, 40, 227-231.	0.8	4
35	Potentiation of Doxorubicin Cytotoxicity by the Calcium Channel Blocker Verapamil in Ehrlich Ascites Cells. Chemotherapy, 1993, 39, 410-415.	0.8	5
36	Glucocorticoid effect on melphalan cytotoxicity, cell-cycle position, cell size, and [3H]uridine incorporation in one of three human melanoma cell lines. Cancer Research, 1987, 47, 4814-20.	0.4	4